Drug intelligence / Profile preview

CVD-001

Development stage: Preclinical
Lead developer: Omic

Overview

CVD-001 is an investigational drug candidate being developed by Omic Analytics for the treatment of hyperlipidemia. Currently in the discovery and lead optimization stage, CVD-001 is designed to target lysophosphatidic acid (LPA), a bioactive phospholipid that plays a significant role in lipid signaling and cardiovascular pathophysiology. By modulating LPA, the drug aims to address the underlying mechanisms of hyperlipidemia. As a preclinical asset, specific details regarding its modality and precise mechanism of action have not yet been disclosed.

Targets

ApoB-100 (Apolipoprotein B-100)

Beyond the preview

Go deeper on CVD-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CVD-001.

Explore the full profile